What does DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE do?

DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is a specialist medical practice in Sint-Niklaas. Private Limited, started on 11 May 2020, 1 establishment.

What is the address of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE?

The registered office of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is located at Bosstraat 6, 9111 Sint-Niklaas.

Is DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE still active?

Yes. According to the CBE (1 October 2026) DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is active, legal situation “Normale toestand”, started on 11 May 2020.

Is DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE registered on Peppol?

Yes, DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is registered on the Peppol network with ID 0208:0746817153.

What is the enterprise number of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE?

The enterprise number of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is BE0746817153.

When was DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE founded?

DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE was founded on 11 May 2020.

Who are the directors of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE?

According to the 2026 annual accounts, the directors of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE are: Vibeke Kruse.

Is DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 May 2020; 5 annual accounts filed, latest fiscal year 2026; 1 directors known from the annual account.

How much profit did DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE make in 2026?

DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE posted a profit after taxes of € 208,735 in financial year 2026.

What is the revenue of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE?

As a small company, DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is not required to publish revenue in its annual accounts. In financial year 2026, its added value was € 288,411.

DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE (Private Limited)

Dossier DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE, printed on 1 October 2026 from databakkes.be/en/0746817153/dr-kruse-vibeke-medische-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2026

DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE from Sint-Niklaas, company number BE0746817153, closed financial year 2026 with a result of € 208,735 after tax. For that financial year DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE recorded a gross margin of € 288,411 and equity of € 176,264. Compared with financial year 2025, the result moved from € 136,321 to € 208,735. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 24, 2026.

What it is worth Growing

€ 176,264

▲ € 133,735 vs 2025

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 208,735

▲ 53% vs 2025

Profit after tax over the fiscal year.

Cash in the bank

€ 161,895

▲ 112% vs 2025

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 75,000 paid out

36 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2026

Vehicles and equipment

€ 16,839

▼ 30% vs 2025

Book value of vehicles, furniture and equipment.

Debts at end 2026

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 4,211

▲ 278% vs 2025

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 592

▼ 85% vs 2025

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	2026	Change 2025 → 2026
Gross margin	€ 122,990 Gross margin 2023: € 122,990 First fiscal year in the series	€ 134,397 Gross margin 2024: € 134,397 ▲ 9% vs 2023 (€ 122,990) Favourable step	€ 188,499 Gross margin 2025: € 188,499 ▲ 40% vs 2024 (€ 134,397) Favourable step	€ 288,411 Gross margin 2026: € 288,411 ▲ 53% vs 2025 (€ 188,499) Favourable step	▲ 53%
Profit after taxes	€ 94,712 Profit after taxes 2023: € 94,712 First fiscal year in the series	€ 102,073 Profit after taxes 2024: € 102,073 ▲ 8% vs 2023 (€ 94,712) Favourable step	€ 136,321 Profit after taxes 2025: € 136,321 ▲ 34% vs 2024 (€ 102,073) Favourable step	€ 208,735 Profit after taxes 2026: € 208,735 ▲ 53% vs 2025 (€ 136,321) Favourable step	▲ 53%
Equity	€ 195,146 Equity 2023: € 195,146 First fiscal year in the series	€ 36,208 Equity 2024: € 36,208 ▼ 81% vs 2023 (€ 195,146) Unfavourable step	€ 42,529 Equity 2025: € 42,529 ▲ 17% vs 2024 (€ 36,208) Favourable step	€ 176,264 Equity 2026: € 176,264 ▲ € 133,735 vs 2025 (€ 42,529) Favourable step	▲ € 133,735
Total debts	€ 33,362 Total debts 2023: € 33,362 First fiscal year in the series	€ 109,210 Total debts 2024: € 109,210 ▲ 227% vs 2023 (€ 33,362) Unfavourable step	€ 136,852 Total debts 2025: € 136,852 ▲ 25% vs 2024 (€ 109,210) Unfavourable step	€ 5,821 Total debts 2026: € 5,821 ▼ 96% vs 2025 (€ 136,852) Favourable step	▼ 96%
Cash	€ 222,339 Cash 2023: € 222,339 First fiscal year in the series	€ 43,801 Cash 2024: € 43,801 ▼ 80% vs 2023 (€ 222,339) Unfavourable step	€ 76,389 Cash 2025: € 76,389 ▲ 74% vs 2024 (€ 43,801) Favourable step	€ 161,895 Cash 2026: € 161,895 ▲ 112% vs 2025 (€ 76,389) Favourable step	▲ 112%
Land & buildings	€ 643 Land & buildings 2023: € 643 First fiscal year in the series	€ 0 Land & buildings 2024: € 0 ▼ 100% vs 2023 (€ 643) Unchanged	-	-
Retained profit	€ 190,146 Retained profit 2023: € 190,146 First fiscal year in the series	€ 31,208 Retained profit 2024: € 31,208 ▼ 84% vs 2023 (€ 190,146) Unfavourable step	€ 37,529 Retained profit 2025: € 37,529 ▲ 20% vs 2024 (€ 31,208) Favourable step	€ 171,264 Retained profit 2026: € 171,264 ▲ € 133,735 vs 2025 (€ 37,529) Favourable step	▲ € 133,735
Dividend	€ 0 Dividend 2023: € 0 First fiscal year in the series	€ 261,012 Dividend 2024: € 261,012 Unchanged (€ 0) Unchanged	€ 130,000 Dividend 2025: € 130,000 ▼ 50% vs 2024 (€ 261,012) Unchanged	€ 75,000 Dividend 2026: € 75,000 ▼ 42% vs 2025 (€ 130,000) Unchanged	▼ 42%
Bank debt	€ 0 Bank debt 2023: € 0 First fiscal year in the series	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 247 Bank debt 2025: € 247 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2026: € 0 ▼ 100% vs 2025 (€ 247) Favourable step	▼ 100%
Balance sheet total	€ 228,508 Balance sheet total 2023: € 228,508 First fiscal year in the series	€ 145,418 Balance sheet total 2024: € 145,418 ▼ 36% vs 2023 (€ 228,508) Unchanged	€ 179,381 Balance sheet total 2025: € 179,381 ▲ 23% vs 2024 (€ 145,418) Unchanged	€ 182,085 Balance sheet total 2026: € 182,085 ▲ 2% vs 2025 (€ 179,381) Unchanged	▲ 2%

Key figures of DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 30 January 2028.

What happened to DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE?

What happened at DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 24, 2026 New annual accounts for financial year 2026: profit of € 208,735 (▲ 53% vs 2025). Source: NBB ↗
Jul 1, 2020 New establishment in Sint-Niklaas. KBO
2020 Vibeke Kruse became a director. NBB
May 11, 2020 Start of the company according to the CBE. KBO

In short

From € 94,712 profit in 2023 to € 208,735 profit in 2026.

Paid € 162,911 in corporate taxes since 2023.

Best year ever: 2026, with € 208,735 profit.

Paid out € 466,012 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE? We notify you, reason included.

Follow DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Vibeke Kruse

DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE

Behind DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE is Vibeke Kruse.

See the full network in the app

Directors

According to the 2026 annual accounts

Vibeke Kruse

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Bosstraat 6

9111 Sint-Niklaas

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0746.817.153
VAT number: BE 0746.817.153
Registered office: Bosstraat 6, 9111 Sint-Niklaas
Names & denominations: DR. KRUSE VIBEKE - MEDISCHE ONCOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 11 May 2020
Peppol: Active · Active since 27 Aug 2025
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗